ASA: Olay Regenerist 'Cell By Cell' Exfoliation Claims Imply 'Physiological' Effects
This article was originally published in The Rose Sheet
Executive Summary
Ads claiming P&G's Olay Regenerist skin-care line “re-energizes skin’s appearance cell by cell” mislead consumers into expecting deeper cellular changes rather than mere surface exfoliation, an implied benefit unsupported by the firm's evidence, according to the UK’s independent regulator.
You may also be interested in...
FDA Warns PhytoCeuticals For Adulterated Cosmetics, Cancer Claims
Agency’s most recently posted warning letters to skin-care marketers include one to PhytoCeuticals for adulterated cosmetics, following an inspection of the company’s manufacturing facility. Osea Internacional and Face Naturals also draw warnings for claims that identify their products as unapproved drugs.
Aligning U.S. With EU Cosmetic Definition Could Enable Claims, Reduce FDA Warnings
Under the European Cosmetics Regulation, cosmetics by definition can “protect” parts of the body and “keep them in good condition,” which provides latitude for structure/function claims that firms do not have in the U.S. While there is interest, particularly among multinationals, for similar license in the states, the tradeoff could be more burdensome requirements for efficacy and safety substantiation that smaller companies could not support.
Regulatory Roulette: Playing In Today’s Skin-Care Market A Gamble
Recent FDA warning letters to skin-care firms raise questions about the regulatory risks companies must assume to compete effectively in today’s marketplace. Former FDAer and EAS Senior Adviser John Bailey discusses the strategic decision before personal-care companies as they develop their marketing and the potential consequences of using structure/function claims.